Chiesi acquires Amryt Pharma to increase commitment to rare disease research

By Liza Laws

- Last updated on GMT

 © Getty Images
© Getty Images

Related tags Rare disease Clinical trials Data management Patient centricity Research

International pharmaceutical company, Chiesi, has taken on Amryt Pharma Plc to show its commitment to developing treatments for rare diseases.

The Chiesi Group is a family business focused on researching for new treatments for rare diseases, respiratory health, and specialty care.

“We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development,” said Giacomo Chiesi, head of Chiesi Global Rare Diseases.

“Amryt has unique and clinically differentiated products and additional promising drugs in its pipeline, and, as a benefit corporation certified B Corp, Chiesi has a patient-centric and sustainable model in place to make these treatments available to even more patients who need them. As of today, we are officially joining our forces to bring hope to people in need and look forward to this new chapter in our collective journey.”

Chiesi Global Rare Diseases (GRD) is part of the Chiesi Group started to find therapies and solutions for people affected by rare diseases. They say the goal of the GRD unit is to ensure equal access so as many people as possible can experience their most fulfilling life. Those who work within the unit collaborate with the rare disease community around the world and say their aim is to bring voice to underserved people in the health care system.

“This acquisition reflects Chiesi Group’s commitment towards patients. Chiesi strives to create a world where it is common to have a therapy for all diseases and acts as a force for good for society and the planet,” said Giuseppe Accogli, CEO of Chiesi Group 

“Amryt Pharma’s team has delivered innovative treatments to rare disease patients with high unmet medical needs. By joining forces and expertise we will be able to grow our capabilities and further strengthen our position to provide a positive impact on patients living with rare diseases.”

Chiesi launched its Boston-based rare diseases unit more than three years ago and has become a dedicated partner to many leaders in patient advocacy, research and care around the world.

At the time Giacomo Chiesi acknowledged that there are more than 7,000 rare diseases, the vast majority with no available treatments. He said the company was excited to put the family business’s drug development and dedication to patients’ experience to work to make a positive difference towards treatment.

Related topics Clinical Development

Related news

Show more

Follow us


View more